Other Head and Neck Sites

Data regarding the use of hypofractionated chemoradiation in the definitive management of head and neck squamous cell carcinoma are increasing. Several prospective and retrospective series have shown local control/response rates comparable to conventional fractionation but increased rates of acute toxicity. There are minimal to no data regarding the use of SBRT as definitive primary treatment in other head and neck disease sites. Limited data support the use of brachytherapy or SBRT as a boost to EBRT in the definitive setting for nasopharyngeal (Chap. 13 ), paranasal sinus, and oropharyngeal SCC.